We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Blog

Screening Living Cells at High-speed
Blog

We recently spoke with Eric Hobbs, CEO at Berkeley Lights to learn more about "digital cell biology". Erik also describes how optofluidics can be used to gain fast, comprehensive measurements and insights across thousands of cells in parallel.

Read More

Uniting Stakeholders to Streamline Drug Discovery
Blog

We recently spoke with Tyler Golato, Lead Scientist at Molecule, to learn more about the "innovation crisis", the factors directly impacting the types of therapeutics being brought to market, and how by uniting stakeholders it is possible to streamline the drug development pipeline.

Read More

DNA and RNA: Why It’s All About Integrity
Blog

In this interview, we spoke with Knut Wintergerst, PhD, General Manager of Biomolecular Systems and Solutions (BSS) and Diagnostics and Genomics Group (DGG) at Agilent to learn more about why DNA and RNA sample integrity is important to scientists and how it can be maintained and analyzed.

Read More

BioAccord LC-MS: Making Mass Spectrometry Available to the Masses
Blog

Earlier in 2019, Waters Corporation announced their BioAccord LC-MS System for biopharmaceutical analysis. We spoke with John Gebler, PhD, Director of Strategic Business Development at Waters Corporation to learn more about the BioAccord System and its applications.

Read More

Simple Eye Measurement Helps Improve Outcomes for Brain Injury Patients
Blog

Pupillometry is an ingenious way of assessing brain health by measuring data from patients’ eyes. New technology has helped standardize pupillometry, and these measurements are now helping treat patients with life-threatening brain injuries. We spoke to Kathleen Pierson, Vice President, Global Sales and Marketing, at pupillometry leader NeurOptics, to find out more.

Read More

Overcoming the Data Analysis Bottleneck in High-throughput Chemistry
Blog

Whilst some aspects of biochemistry research have become increasingly high-throughput, other, like analysis of chemical data, are too often laborious and slow. We talked to Andrew Anderson, Vice President of Innovation and Informatics Strategy at ACD/Labs about how the field is being changed by automation and how Katalyst hopes to speed up pharmaceutical development.

Read More

Zika vs Dengue: Minimizing Cross-reactivity in Immunoassay Development
Blog

The Zika virus poses a significant global risk, and there is currently no vaccine or specific treatment available for those infected. Having access to sensitive and specific diagnostic assays is essential to disease management, and in enabling effective research and the development of therapeutics. We spoke to Nick Roesen, Founder and COO of The Native Antigen Company, to learn about the Zika virus immunoassays that have been developed to overcome cross-reactivity with Dengue.

Read More

The Way Forward for Antibodies in Neuroscience
Blog

Antibodies are an essential part of everyday neuroscience research. But recently, high-profile criticism has cast doubt on their reliability and reproducibility. We caught up with Bio-Techne’s Raymond Chan and Katherine Bradley to find out how providers are hoping to improve antibodies and make them fit for a more reproducible future in neuroscience.

Read More

Into the Cloud: How Pharmaceutical and Biotechnology Companies Can Balance Cybersecurity With Efficient Data Sharing
Blog

The pharmaceutical and biotechnology industry is the number one target for cybercriminals, according to recent survey. Unsurprisingly, data security is now top of the agenda for most companies in this sector. How can organizations balance robust cybersecurity with the need for efficient flow of information between colleagues and collaborators?

Read More

Colorectal Cancer Blood Test Driven by Immuno-transcriptomics
Blog

By studying gene expression modifications induced by the immune response, Novigenix has developed a blood test for colorectal cancer. This Q&A with Jan Groen, CEO, provides insights on the test, and on the field of study that could revolutionize cancer diagnosis.

Read More